1,429
Views
14
CrossRef citations to date
0
Altmetric
Paper from the 20th Summerschool in Immunotoxicology, Beaune, France, Sept. 26–28, 2011

The Göttingen minipig® as an alternative non-rodent species for immunogenicity testing: A demonstrator study using the IL-1 receptor antagonist anakinra

, , , , , , , & show all
Pages 96-105 | Received 02 Jul 2012, Accepted 25 Sep 2012, Published online: 07 Nov 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Geertje J. D. van Mierlo, Nicole H. P. Cnubben, Diana Wouters, Gerrit Jan Wolbink, Margreet H. L. Hart, Theo Rispens, Niels-Christian Ganderup, C. Frieke Kuper, Lucien Aarden & André H. Penninks. (2014) The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab. Journal of Immunotoxicology 11:1, pages 62-71.
Read now

Articles from other publishers (13)

Tomasz Grabowski, Rafał Derlacz & Artur Burmańczuk. (2022) Göttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation. Biomedicine & Pharmacotherapy 156, pages 113926.
Crossref
Tomasz Grabowski, Artur Burmańczuk, Rafał Derlacz, Tadeusz Stefaniak, Anna Rząsa & Jacek Borkowski. (2021) Ustekinumab pharmacokinetics after subcutaneous administration in swine model. Journal of Veterinary Science 22:5.
Crossref
Yong-Wook Son, Ha-Ni Choi, Jeong-Hwan Che, Byeong-Cheol Kang & Jun-Won Yun. (2020) Advances in selecting appropriate non-rodent species for regulatory toxicology research: Policy, ethical, and experimental considerations. Regulatory Toxicology and Pharmacology 116, pages 104757.
Crossref
Jacques Descotes, Linda Allais, Philippe Ancian, Henrik Duelund Pedersen, Claire Friry-Santini, Antonio Iglesias, Tina Rubic-Schneider, Hollie Skaggs & Peter Vestbjerg. (2018) Nonclinical evaluation of immunological safety in Göttingen Minipigs: The CONFIRM initiative. Regulatory Toxicology and Pharmacology 94, pages 271-275.
Crossref
Wim Jiskoot, Grzegorz Kijanka, Theodore W. Randolph, John F. Carpenter, Atanas V. Koulov, Hanns-Christian Mahler, Marisa K. Joubert, Vibha Jawa & Linda O. Narhi. (2016) Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges. Journal of Pharmaceutical Sciences 105:5, pages 1567-1575.
Crossref
Joshua A. Jackman, Tamás Mészáros, Tamás Fülöp, Rudolf Urbanics, Janos Szebeni & Nam-Joon Cho. (2016) Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model. Nanomedicine: Nanotechnology, Biology and Medicine 12:4, pages 933-943.
Crossref
Tina Rubic-Schneider, Brigitte Christen, Dominique Brees & Michael Kammüller. (2016) Minipigs in Translational Immunosafety Sciences. Toxicologic Pathology 44:3, pages 315-324.
Crossref
Karina Gutierrez, Naomi Dicks, Werner G. Glanzner, Luis B. Agellon & Vilceu Bordignon. (2015) Efficacy of the porcine species in biomedical research. Frontiers in Genetics 6.
Crossref
Mihaela Peric, Ivo Dumic-Cule, Danka Grcevic, Mario Matijasic, Donatella Verbanac, Ruth Paul, Lovorka Grgurevic, Vladimir Trkulja, Cedo M. Bagi & Slobodan Vukicevic. (2015) The rational use of animal models in the evaluation of novel bone regenerative therapies. Bone 70, pages 73-86.
Crossref
Georg Schmitt, Paul Barrow & Markus Stephan-Gueldner. 2015. The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment. The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment 337 355 .
John Webster. (2014) Ethical and Animal Welfare Considerations in Relation to Species Selection for Animal Experimentation. Animals 4:4, pages 729-741.
Crossref
Takuya Suzuki, Masako Ichihara, Kenji Hyodo, Eiichi Yamamoto, Tatsuhiro Ishida, Hiroshi Kiwada, Hiroshi Kikuchi & Hiroshi Ishihara. (2014) Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin. International Journal of Pharmaceutics 476:1-2, pages 205-212.
Crossref
Niels-Christian Ganderup. 2014. Biomarkers in Toxicology. Biomarkers in Toxicology 71 91 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.